Artigo
Revisado por pares
Cost-effectiveness analysis of tislelizumab plus chemotherapy versus standard chemotherapy in first-line treatment for extensive-stage small cell lung cancer: perspectives from the United States and China
2024; Springer Science+Business Media; Linguagem: Inglês
10.1007/s11096-024-01802-1
ISSN2210-7711
AutoresW.J. Lang, Qi Ai, Yulong He, Yu‐Fei Pan, Qinling Jiang, Ming Ouyang, Tianshou Sun,
Tópico(s)Lung Cancer Treatments and Mutations
Referência(s)